USD 0.587
↓ -0.024 (-3.93%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| TCBP | -3.9 | -38.3 | -88.4 | -85.5 | -94.8 | -99.4 | -100.0 | -100.0 | -100.0 | -100.0 |
| S&P 500 | -0.5 | -2.1 | 0.0 | 4.6 | 10.6 | 29.0 | 24.9 | 88.0 | 186.3 | 33114.9 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | TCBP |
| name | TC Biopharm (Holdings) Plc |
| price | 0.59 |
| changes percentage | -3.93 |
| change | -0.02 |
| day low | 0.58 |
| day high | 0.63 |
| year high | 138 |
| year low | 0.56 |
| market cap | 187554 |
| price avg 50 | 3.96 |
| price avg 200 | 8.99 |
| exchange | NASDAQ |
| volume | 234203 |
| avg volume | 1202942 |
| open | 0.62 |
| previous close | 0.61 |
| eps | -192.53 |
| pe | 0 |
| earnings announcement | 2024-11-27T12:00:00.000+0000 |
| shares outstanding | 319513 |
| timestamp | 2024-11-19 15:12:21 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001872812 | |||
| revenue | 0 | 3844532 | -100.00 |
| gross profit | 0 | 3844532 | -100.00 |
| gross profit ratio | 0 | 1 | -100.00 |
| research and development expenses | 7771391 | 7592470 | 2.36 |
| operating expenses | 6912657 | 124901 | 5,434.51 |
| interest income | 83025 | 6753231 | -98.77 |
| interest expense | 0 | 6753231 | -100.00 |
| ebitda | -13609267 | -11321526 | -20.21 |
| ebitdaratio | 0 | -2.94 | 100.00 |
| operating income | -14239323 | -12083997 | -17.84 |
| operating income ratio | 0 | -3.14 | 100.00 |
| net income | -5906953 | -1313601 | -349.68 |
| net income ratio | 0 | -0.34 | 100.00 |
| eps | -191.21 | -382.31 | 49.99 |
Revenue Growth: revenue decreased to 0 million in 2023 from 4 million in 2022 representing a change of -100.0%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 0 million in 2023 from 4 million in 2022 representing a change of -100.0%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 7 million in 2023 from 0 million in 2022 representing a change of 5434.51%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Research and Development (R&D) Expenses: R&D Expenses increased to 8 million in 2023 from 8 million in 2022 representing a change of 2.36%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -14 million in 2023 from -11 million in 2022 representing a change of -20.21%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -14 million in 2023 from -12 million in 2022 representing a change of -17.84%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -6 million in 2023 from -1 million in 2022 representing a change of -349.68%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -191.21 in 2023 from -191.21 in 2022 representing a change of 49.99%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2024Q1 | 2023Q4 | Q/Q change % | |
|---|---|---|---|
| 0001872812 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | 0 | NaN |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 1298942 | 1846809 | -29.67 |
| operating expenses | 3441656 | 3354746 | 2.59 |
| interest income | 0 | 30115 | -100.00 |
| interest expense | 0 | 0 | NaN |
| ebitda | -3314635 | -3132555 | -5.81 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -3441656 | -3276836 | -5.03 |
| operating income ratio | 0 | 0 | NaN |
| net income | -3321854 | -3130268 | -6.12 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.11 | -67.13 | 99.84 |
Research and Development (R&D) Expenses: R&D Expenses decreased to 1 million in 2024Q1 from 2 million in 2023Q4 representing a change of -29.67%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 3 million in 2024Q1 from 3 million in 2023Q4 representing a change of 2.59%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -3 million in 2024Q1 from -3 million in 2023Q4 representing a change of -5.81%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -3 million in 2024Q1 from -3 million in 2023Q4 representing a change of -5.03%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -3 million in 2024Q1 from -3 million in 2023Q4 representing a change of -6.12%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -0.11 in 2024Q1 from -0.11 in 2023Q4 representing a change of 99.84%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001872812 | |||
| total assets | 8931664 | 11291977 | -20.90 |
| total liabilities | 6246434 | 10960712 | -43.01 |
| total equity | 2685230 | 331265 | 710.60 |
| cash and cash equivalents | 2462609 | 4808060 | -48.78 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 5700927 | 7447516 | -23.45 |
| total non current assets | 3230737 | 3844461 | -15.96 |
| total current liabilities | 4750601 | 9163877 | -48.16 |
| total non current liabilities | 1495833 | 1796835 | -16.75 |
| common stock | 2057 | 397493 | -99.48 |
| retained earnings | -38837290 | -33374796 | -16.37 |
| total debt | 1801157 | 2450319 | -26.49 |
Total Assets: Total Assets decreased to 9 million in 2023 from 11 million in 2022 representing a change of -20.9%. Suggesting a decrease in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 2 million in 2023 from 5 million in 2022 representing a change of -48.78%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 6 million in 2023 from 7 million in 2022 representing a change of -23.45%. This indicates a worsen liquidity position.
Common Stock: Common Stock decreased to 0 in 2023 from 0 in 2022 representing a change of -99.48%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -39 million in 2023 from -33 million in 2022 representing a change of -16.37%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 6 million in 2023 from 11 million in 2022 representing a change of -43.01%. This indicates a decrease in overall liabilities.
Total Equity: Total Equity increased to 3 million in 2023 from 0 million in 2022 representing a change of 710.6%. This indicates an increase in shareholders' equity.
Total Current Liabilities: Total Current Liabilities decreased to 5 million in 2023 from 9 million in 2022 representing a change of -48.16%. This indicates a lower short-term debt burden.
Total Debt: Total Debt decreased to 2 million in 2023 from 2 million in 2022 representing a change of -26.49%. This indicates a reduction in overall debt burden.
| 2024Q1 | 2023Q4 | Q/Q change % | |
|---|---|---|---|
| 0001872812 | |||
| total assets | 7264053 | 8931664 | -18.67 |
| total liabilities | 6183565 | 6246434 | -1.01 |
| total equity | 1080488 | 2685230 | -59.76 |
| cash and cash equivalents | 980955 | 2462609 | -60.17 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 4202780 | 5700927 | -26.28 |
| total non current assets | 3061273 | 3230737 | -5.25 |
| total current liabilities | 4763596 | 4750601 | 0.27 |
| total non current liabilities | 1419969 | 1495833 | -5.07 |
| common stock | 6391 | 399455 | -98.40 |
| retained earnings | -42159144 | -38837290 | -8.55 |
| total debt | 1728127 | 1495833 | 15.53 |
Total Assets: Total Assets decreased to 7 million in 2024Q1 from 9 million in 2023Q4 representing a change of -18.67%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 1 million in 2024Q1 from 3 million in 2023Q4 representing a change of -59.76%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 1 million in 2024Q1 from 2 million in 2023Q4 representing a change of -60.17%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 4 million in 2024Q1 from 6 million in 2023Q4 representing a change of -26.28%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 5 million in 2024Q1 from 5 million in 2023Q4 representing a change of 0.27%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 0 in 2024Q1 from 0 in 2023Q4 representing a change of -98.4%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -42 million in 2024Q1 from -39 million in 2023Q4 representing a change of -8.55%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 2 million in 2024Q1 from 1 million in 2023Q4 representing a change of 15.53%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 6 million in 2024Q1 from 6 million in 2023Q4 representing a change of -1.01%. This indicates a decrease in overall liabilities.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001872812 | |||
| net change in cash | -2345451 | 3241372 | -172.36 |
| operating cash flow | -10544870 | -15292297 | 31.04 |
| free cash flow | -10655223 | -15533009 | 31.40 |
| capital expenditure | -110353 | -240712 | 54.16 |
| depreciation and amortization | 633008 | 959048 | -34.00 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 444459 | 1123250 | -60.43 |
| accounts payables | 0 | 0 | NaN |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -110353 | -240712 | 54.16 |
| net cash used for investing activites | -208789 | -310197 | 32.69 |
| debt repayment | 0 | -2614214 | 100.00 |
| common stock issued | 4186862 | 3369877 | 24.24 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 8520376 | 18653214 | -54.32 |
| cash at end of period | 2462609 | 4808060 | -48.78 |
| accounts receivables | 676407 | -37503 | 1,903.61 |
| cash at beginning of period | 4808060 | 1566688 | 206.89 |
Net Change in Cash: Net Change in Cash decreased to -2 million in 2023 from 3 million in 2022 representing a change of -172.36%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure increased to 0 million in 2023 from 0 million in 2022 representing a change of 54.16%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Receivables: Accounts Receivables increased to 1 in 2023 from 0 million in 2022 representing a change of 1903.61%. This suggests that the company is less capable of collecting payments from its customers.
Operating Cash Flow: Operating Cash Flow increased to -11 million in 2023 from -15 million in 2022 representing a change of 31.04%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -11 million in 2023 from -16 million in 2022 representing a change of 31.4%. This indicates an increase in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation decreased to 0 million in 2023 from 1 million in 2022 representing a change of -60.43%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
| 2024Q1 | 2023Q4 | Q/Q change % | |
|---|---|---|---|
| 0001872812 | |||
| operating cash flow | -2408593 | -1996632 | -20.63 |
| free cash flow | -2414211 | -1972378 | -22.40 |
| capital expenditure | -5618 | 24254 | -123.16 |
| depreciation and amortization | 127021 | 189890 | -33.11 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 784555 | 151069 | 419.34 |
| accounts receivables | 0 | -792009 | 100.00 |
| accounts payables | 0 | 0 | NaN |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | 0 | 24254 | -100.00 |
| net cash used for investing activites | -5618 | 4018 | -239.82 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 19765 | 0 | NaN |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 932557 | 2261163 | -58.76 |
| net change in cash | -1481654 | 0 | NaN |
| cash at end of period | 980955 | 0 | NaN |
| cash at beginning of period | 2462609 | 0 | NaN |
Net Change in Cash: Net Change in Cash decreased to -1 million in 2024Q1 from 0 million in 2023Q4 representing a change of nan%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -2 million in 2024Q1 from -2 million in 2023Q4 representing a change of -20.63%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -2 million in 2024Q1 from -2 million in 2023Q4 representing a change of -22.4%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 1 million in 2024Q1 from 0 million in 2023Q4 representing a change of 419.34%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Receivables: Accounts Receivables increased to 0 in 2024Q1 from -1 million in 2023Q4 representing a change of 100.0%. This suggests that the company is less capable of collecting payments from its customers.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q1 from 0 million in 2023Q4 representing a change of -123.16%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0 | 1118.9 | -100.00 |
| net income per share | -191.21 | -382.31 | 49.98 |
| operating cash flow per share | -341.35 | -4450.62 | 92.33 |
| free cash flow per share | -344.92 | -4520.67 | 92.37 |
| cash per share | 79.72 | 1399.32 | -94.30 |
| book value per share | 86.92 | 96.41 | -9.84 |
| tangible book value per share | 67.01 | -64.54 | 203.83 |
| shareholders equity per share | 86.92 | 96.41 | -9.84 |
| interest debt per share | 48.42 | 2155.62 | -97.75 |
| market cap | 770005.03 | 2187187.08 | -64.79 |
| enterprise value | 108553.03 | -170553.92 | 163.65 |
| pe ratio | -0.13 | -1.67 | 92.17 |
| price to sales ratio | 0 | 0.57 | -100.00 |
| pocfratio | -0.07 | -0.14 | 48.94 |
| pfcf ratio | -0.07 | -0.14 | 48.68 |
| pb ratio | 0.29 | 6.6 | -95.66 |
| ptb ratio | 0.29 | 6.6 | -95.66 |
| ev to sales | 0 | -0.04 | 100.00 |
| enterprise value over ebitda | -0.01 | 0.02 | -152.95 |
| ev to operating cash flow | -0.01 | 0.01 | -192.30 |
| ev to free cash flow | -0.01 | 0.01 | -192.78 |
| earnings yield | -7.67 | -0.6 | -1,177.30 |
| free cash flow yield | -13.84 | -7.1 | -94.85 |
| debt to equity | 0.56 | 1.97 | -71.76 |
| debt to assets | 0.17 | 0.06 | 189.39 |
| net debt to ebitda | 0.05 | 0.21 | -76.66 |
| current ratio | 1.2 | 0.81 | 47.66 |
| interest coverage | 0 | -1.79 | 100.00 |
| income quality | 1.79 | 11.64 | -84.67 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 2.17 | -100.00 |
| research and ddevelopement to revenue | 0 | 1.97 | -100.00 |
| intangibles to total assets | 0.07 | 0.05 | 40.64 |
| capex to operating cash flow | -0.01 | -0.02 | 33.52 |
| capex to revenue | 0 | 0.06 | -100.00 |
| capex to depreciation | 0.17 | 0.25 | -30.54 |
| stock based compensation to revenue | 0 | 0.29 | -100.00 |
| graham number | 611.53 | 910.66 | -32.85 |
| roic | -2.88 | -19.23 | 85.04 |
| return on tangible assets | -0.71 | -0.12 | -480.66 |
| graham net net | -122.49 | -1790.65 | 93.16 |
| working capital | 950326 | -1716361 | 155.37 |
| tangible asset value | 2070060 | -221751 | 1,033.51 |
| net current asset value | -545507 | -3513196 | 84.47 |
| invested capital | 4181063 | 2128100 | 96.47 |
| average receivables | 0 | 0 | NaN |
| average payables | 1364821.5 | 1152378.5 | 18.44 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0 | NaN |
| inventory turnover | 0 | 0 | NaN |
| roe | -2.2 | -3.97 | 44.53 |
| capex per share | 3.57 | 70.06 | -94.90 |
ROE: Return on Equity (ROE) increased to -2.20 on 2023-12-31 from -3.97 on 2022-12-31, representing a change of 44.53%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.13 on 2023-12-31 from -1.67 on 2022-12-31, representing a change of 92.17%. Indicating an increase in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 1.20 on 2023-12-31 from 0.81 on 2022-12-31, representing a change of 47.66%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Also, it's above 1, indicating the ability to cover short-term obligations.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.56 on 2023-12-31 from 1.97 on 2022-12-31, representing a change of -71.76%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-03-31 Q1 | 2023-12-31 Q4 | Q/Q change % | |
|---|---|---|---|
| TCBP | |||
| calendar year | 2024 | 2023 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.11 | -67.13 | 99.84 |
| operating cash flow per share | -0.08 | -42.82 | 99.81 |
| free cash flow per share | -0.08 | -42.3 | 99.81 |
| cash per share | 0.03 | 52.81 | -99.94 |
| book value per share | 0.04 | 57.59 | -99.94 |
| tangible book value per share | 0.02 | 44.39 | -99.96 |
| shareholders equity per share | 0.04 | 57.59 | -99.94 |
| interest debt per share | 0.05 | 0 | NaN |
| market cap | 304925949.5 | 1162285.86 | 26,135.02 |
| enterprise value | 305673121.5 | 195509.86 | 156,246.65 |
| pe ratio | -22.95 | -0.09 | -24,621.93 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -126.6 | -0.58 | -21,647.84 |
| pfcf ratio | -126.3 | -0.59 | -21,333.66 |
| pb ratio | 282.21 | 0.43 | 65,099.31 |
| ptb ratio | 282.21 | 0.43 | 65,099.31 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -92.22 | -0.06 | -147,658.20 |
| ev to operating cash flow | -126.91 | -0.1 | -129,505.43 |
| ev to free cash flow | -126.61 | -0.1 | -127,633.12 |
| earnings yield | -0.01 | -2.69 | 99.60 |
| free cash flow yield | -0.01 | -1.7 | 99.53 |
| debt to equity | 1.31 | 0 | NaN |
| debt to assets | 0.2 | 0 | NaN |
| net debt to ebitda | -0.23 | 0.31 | -173.04 |
| current ratio | 0.88 | 1.2 | -26.48 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.73 | 0.64 | 13.68 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0.08 | 0.07 | 21.63 |
| capex to operating cash flow | -0.0 | -0.01 | 80.80 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.04 | 0.13 | -65.37 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 0.3 | 294.92 | -99.90 |
| roic | -1.33 | -1.29 | -3.12 |
| return on tangible assets | -0.5 | -0.38 | -32.60 |
| graham net net | -0.17 | -81.15 | 99.79 |
| working capital | -560816 | 950326 | -159.01 |
| tangible asset value | 471976 | 2070060 | -77.20 |
| net current asset value | -1980785 | -545507 | -263.11 |
| invested capital | 2500457 | 4181063 | -40.20 |
| average receivables | 0 | 0 | NaN |
| average payables | 1887445.5 | 1847279 | 2.17 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0 | NaN |
| inventory turnover | 0 | 0 | NaN |
| roe | -3.07 | -1.17 | -163.73 |
| capex per share | 0.0 | 0.52 | -99.96 |
ROE: Return on Equity (ROE) decreased to -3.07 on 2024-03-31 Q1 from -1.17 on 2023-12-31 Q4, representing a change of -163.73%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -22.95 on 2024-03-31 Q1 from -0.09 on 2023-12-31 Q4, representing a change of -24621.93%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 0.88 on 2024-03-31 Q1 from 1.20 on 2023-12-31 Q4, representing a change of -26.48%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-12 09:30:00
EDINBURGH, Scotland , Nov. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has been awarded non-dilutive funding of $250,000 from the G-Rex® Grant Program. The G-Rex® Grant Program, launched by ScaleReady alongside Wilson Wolf Manufacturing and the Bio-Techne Corporation, is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing.
Sentiment: Negative
Publish Date: 2024-10-30 08:30:00
EDINBURGH, Scotland , Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today provides an update to its shareholders and highlighted the Company's operational achievements thus far in 2024. "The Company has made tremendous strides during the current year and bolstered its standing as a leading clinical-stage biopharmaceutical company," said Bryan Kobel, CEO of TC BioPharm.
Sentiment: Negative
Publish Date: 2024-10-25 09:45:00
TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchange EDINBURGH, Scotland , Oct. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today refuted a false claim made earlier this week on social media, stating there is absolutely no way the company is in any danger of being delisted from the Nasdaq stock exchange. The since deleted rumor stated that the company had filed an 8-K Notice to "Delist" from the Nasdaq and would transfer trading to a different exchange.
Sentiment: Positive
Publish Date: 2024-10-22 08:30:00
EDINBURGH, Scotland , Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treatment for Monkeypox. Dr. Carlos Maluquer de Motes is Reader and Principal Investigator at the University of Surrey, United Kingdom and works closely with The Pirbright Institute, a leading center of excellence in research of viral diseases that spread from animals to humans.
Sentiment: Positive
Publish Date: 2024-10-03 08:30:00
TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the donor screening and matching process The software could have additional applications across cell therapy for donor/patient matching EDINBURGH, Scotland , Oct. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a sponsored research agreement with Carnegie Mellon University to explore the potential use of artificial intelligence to optimize the patient screening process. The Company will partner with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the School of Computer Science at the renowned university, and her lab to leverage AI to build a solution that enhances the donor selection process and matching process.
Sentiment: Negative
Publish Date: 2024-09-25 08:30:00
Additional London-based clinic to increase enrolment velocity Leading hospital with extensive cell therapy and oncology trial experience EDINBURGH, Scotland , Sept. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced new site opening of Guys and St. Thomas Hospital in the ACHIEVE UK Trial.
Sentiment: Negative
Publish Date: 2024-09-24 08:45:00
EDINBURGH, Scotland , Sept. 24, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that Chief Executive Officer Bryan Kobel has been invited to present at the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York City.
Sentiment: Negative
Publish Date: 2024-09-12 08:30:00
No TCB008-related Adverse Events seen in any of the re-start patients 6 Patients received second dose, 3 Patients received third dose, 1 Patient received fourth dose EDINBURGH, Scotland, Sept. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients.
Sentiment: Negative
Publish Date: 2024-09-09 08:30:00
EDINBURGH, Scotland , Sept. 9, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox.
Sentiment: Negative
Publish Date: 2024-09-06 16:00:00
EDINBURGH, Scotland , Sept. 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB 008, for treatment in monkey pox.
Sentiment: Negative
Publish Date: 2024-09-05 08:30:00
EDINBURGH, Scotland , Sept. 5, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications today announced it will participate at the H.C.
Sentiment: Negative
Publish Date: 2024-09-03 08:30:00
5 New patients dosed, bringing total to 6 patients dosed in ACHIEVE at higher dose level 5 Patients received second dose 2 Patients received third dose EDINBURGH, Scotland , Sept. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announces dosing of 5 new patients in the ACHIEVE Phase 2b trial ongoing in the UK.
Sentiment: Negative
Publish Date: 2024-08-28 17:15:00
EDINBURGH, Scotland , Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of its previously announced public offering, upsized to 6,000,000 shares of its American Depository Shares ("ADSs")(or pre-funded warrants in lieu thereof), together with Series H warrants ("Series G Warrants") to purchase up to 6,000,000 ADSs at a combined public offering price of $1 per ADS (or pre-funded warrant in lieu thereof) and associated Series H Warrant. The Series H Warrants have an exercise price of £0.76 per ADS, are exercisable upon issuance and will expire one year from the date of issuance.
Sentiment: Negative
Publish Date: 2024-08-28 13:50:00
EDINBURGH, Scotland , Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has received a patent grant from European Patent Office (EPO) covering the use of modified gamma delta cells for the treatment of cancer and viral indications. The Company intends to proceed with the patent process in specific European countries in line with the commercial strategy of TCBP.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
